Drugs that contain Ixabepilone
1. Ixempra Kit patents expiration
IXEMPRA KIT Litigations
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US7125899 | R-PHARM US LLC | Epothilone derivatives |
May, 2018
(5 years ago) | |
| USRE41911 | R-PHARM US LLC | Epothilone derivatives |
Sep, 2020
(3 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
|
US7125899 (Pediatric) | R-PHARM US LLC | Epothilone derivatives |
Nov, 2018
(5 years ago) | |
|
USRE41911 (Pediatric) | R-PHARM US LLC | Epothilone derivatives |
Mar, 2021
(3 years ago) | |
| US6670384 | R-PHARM US LLC | Methods of administering epothilone analogs for the treatment of cancer |
Jan, 2022
(2 years ago) | |
| US7022330 | R-PHARM US LLC | Parenteral formulation for epothilone analogs |
Jan, 2022
(2 years ago) | |
| USRE41393 | R-PHARM US LLC | Treatment of refractory tumors using epothilone derivatives |
Feb, 2022
(2 years ago) | |
|
US6670384 (Pediatric) | R-PHARM US LLC | Methods of administering epothilone analogs for the treatment of cancer |
Jul, 2022
(1 year, 9 months ago) | |
|
US7022330 (Pediatric) | R-PHARM US LLC | Parenteral formulation for epothilone analogs |
Jul, 2022
(1 year, 9 months ago) | |
|
USRE41393 (Pediatric) | R-PHARM US LLC | Treatment of refractory tumors using epothilone derivatives |
Aug, 2022
(1 year, 8 months ago) | |
| US7312237 | R-PHARM US LLC | Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases |
Aug, 2024
(3 months from now) | |
|
US7312237 (Pediatric) | R-PHARM US LLC | Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases |
Feb, 2025
(9 months from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 16, 2012 |
| M(M-61) | Oct 18, 2014 |
| Pediatric Exclusivity(PED) | Apr 18, 2015 |
NCE-1 date: 18 April, 2014
Market Authorisation Date: 16 October, 2007
Treatment: Method of treating cancer, iv admin, lyophilized ixabepilone diluted, every week or 3 weeks; Lyophilized ixabepilone with solvent(dehydrated ethanol) diluted to concentration of 0.1mg/ml to 0.9mg/ml...
Dosage: INJECTABLE;INTRAVENOUS
How can I launch a generic of IXEMPRA KIT before it's drug patent expiration?
More Information on Dosage
IXEMPRA KIT family patents
